Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 11/20 | 0.72 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | HTR7 | P34969 | 1/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28945875 | 0.87 | TAAR1 (0.77) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL28964100 | 0.85 | TAAR1 (0.74) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL14903761 | 0.84 | TAAR1 (1.00) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL2042943 | 0.84 | TAAR1 (1.00) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL14903760 | 0.81 | TAAR1 (0.76) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL2037558 | 0.81 | TAAR1 (0.76) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| Hydrochloric Acid SCHEMBL28514686 | 0.80 | TAAR1 (0.74) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL14903730 | 0.80 | TAAR1 (1.00) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL14903739 | 0.80 | TAAR1 (1.00) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL21282227 | 0.80 | TAAR1 (0.71) | TAAR1HTR1ADRD2HTR7KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1409476-B1 | PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY | LILLY CO ELI (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040180883-A1 | Pharmaceutical compounds with serotonin receptor activity | GILMORE JEREMY (GB) | 2004-09-16 | — | — | US | disclosed |
| EP-1409476-A1 | PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY | ELI LILLY AND COMPANY (US) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003006455-A1 | PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY | ELI LILLY AND COMPANY (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180883-A1 | Pharmaceutical compounds with serotonin receptor activity | HTR1A, HTR5A, HTR1E | TAAR1 150/4885HTR1A 1/4885DRD2 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.